Literature DB >> 16174239

Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer.

C-H Chen1, J Shen, W-J Lee, S-N Chow.   

Abstract

Cyclin D1 and c-Myc are key participants in the cell-cycle pathway, in which aberrancies have been associated with malignant transformation. To date, data on the relationship of expression of these proteins and histologic subtype of epithelial ovarian cancer are still scarce and discordant. Immunohistochemical analysis was performed on 12 normal ovaries and 47 cases of serous, mucinous, endometrioid, and clear cell ovarian carcinomas. No abnormal expression of cyclin D1 or c-Myc was demonstrated in any of the 12 normal ovarian specimens. However, compared to normal ovarian tissues, overexpression of cyclin D1 and c-Myc was observed in 42.6% (20/47) and 65.9% (31/47) of tumors examined, respectively. There was no significant difference of overexpression of cyclin D1 or c-Myc gene products between these four histologic subtypes of ovarian adenocarcinomas. This study shows that cyclin D1 and c-Myc are frequently overexpressed in epithelial ovarian carcinomas, but they are not correlated with a particular histologic subtype. Although our preliminary results need to be validated in a larger number of tumors, the abnormal expression of cyclin D1 and c-Myc in epithelial ovarian cancer reaffirms the notion that they are crucial components in the pathway of tumorigenesis and deserve further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16174239     DOI: 10.1111/j.1525-1438.2005.00150.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  24 in total

1.  Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Authors:  Sara Previdi; Anastasia Malek; Veronica Albertini; Cristina Riva; Carlo Capella; Massimo Broggini; Giuseppina M Carbone; Jurgen Rohr; Carlo V Catapano
Journal:  Gynecol Oncol       Date:  2010-05-08       Impact factor: 5.482

2.  p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.

Authors:  Tulsiram Prathapam; Alexey Aleshin; Yinghui Guan; Joe W Gray; G Steven Martin
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

3.  BRCA1-mediated signaling pathways in ovarian carcinogenesis.

Authors:  Tejaswita M Karve; Xin Li; Tapas Saha
Journal:  Funct Integr Genomics       Date:  2011-09-02       Impact factor: 3.410

4.  Cells lacking IKKα show nuclear cyclin D1 overexpression and a neoplastic phenotype: role of IKKα as a tumor suppressor.

Authors:  Youn-Tae Kwak; Sofyan M Radaideh; Lianghao Ding; Rui Li; Eugene Frenkel; Michael D Story; Luc Girard; John Minna; Udit N Verma
Journal:  Mol Cancer Res       Date:  2011-02-11       Impact factor: 5.852

Review 5.  Ovarian clear cell adenocarcinoma: a continuing enigma.

Authors:  David S P Tan; Stan Kaye
Journal:  J Clin Pathol       Date:  2006-10-03       Impact factor: 3.411

6.  Functional genomics identifies therapeutic targets for MYC-driven cancer.

Authors:  Masafumi Toyoshima; Heather L Howie; Maki Imakura; Ryan M Walsh; James E Annis; Aaron N Chang; Jason Frazier; B Nelson Chau; Andrey Loboda; Peter S Linsley; Michele A Cleary; Julie R Park; Carla Grandori
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-23       Impact factor: 11.205

Review 7.  The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics.

Authors:  Tracy A Brooks; Laurence H Hurley
Journal:  Nat Rev Cancer       Date:  2009-11-12       Impact factor: 60.716

8.  SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma.

Authors:  Z Zhao; J Ma; K Wu; L Chen; J Yu; W Hu; K Zhang
Journal:  Clin Transl Oncol       Date:  2015-11-13       Impact factor: 3.405

Review 9.  Opposing functions of psoriasin (S100A7) and koebnerisin (S100A15) in epithelial carcinogenesis.

Authors:  Eva Hattinger; Stephanie Zwicker; Thomas Ruzicka; Stuart H Yuspa; Ronald Wolf
Journal:  Curr Opin Pharmacol       Date:  2013-05-09       Impact factor: 5.547

10.  Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.

Authors:  Naoki Kawahara; Kenji Ogawa; Mika Nagayasu; Mai Kimura; Yoshikazu Sasaki; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.